Lataa...
Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia
Evolocumab, a novel human monoclonal antibody, inhibits proprotein convertase subtilisin/kexin type 9, a protein that targets low-density lipoprotein-cholesterol (LDL-C) receptors for the treatment of hyperlipidemia. The primary objective of this analysis was to characterize the population pharmacok...
Tallennettuna:
| Julkaisussa: | J Pharmacokinet Pharmacodyn |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer US
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5953983/ https://ncbi.nlm.nih.gov/pubmed/29736889 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10928-018-9592-y |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|